Sen. Mike Braun

Maddy summaryS 1131, the Drug Price Transparency Act of 2023, requires drug manufacturers to make price discounts visible to patients at checkout and ensures transparency in fees paid to pharmacy benefit managers (PBMs). It directly affects drug manufacturers, PBMs, and health insurance plans (including Medicare Part D, private plans, and ERISA-covered plans) by eliminating hidden rebates and mandating that any price reduction for covered drugs appears at the point of sale. The bill allows only two types of arrangements: discounts shown to patients or flat-fee service payments to PBMs that are transparent to health plans. It takes effect January 1, 2024, and focuses on making pricing clear without setting new price limits.

Maddy summaryThis bill raises the gross receipts threshold for most nonprofits from $5,000 to $50,000 before they must file detailed annual reports with the IRS. It exempts certain organizations, like those focused solely on investments (not lobbying or political activity), from reporting donor names and addresses. The changes apply to tax years beginning after the bill's enactment, reducing reporting burdens for smaller nonprofits and protecting donor privacy for qualifying groups. These provisions directly affect thousands of local nonprofits and community organizations that previously faced higher administrative costs.

Maddy summaryS 1103 requires healthcare providers to notify a minor's parents (or legal guardians) in writing before performing an abortion on an unemancipated minor under 18, with exceptions for medical emergencies or documented parental abuse. It mandates a 96-hour waiting period after notification and allows parents to seek a court injunction to block the abortion. The bill prohibits abortion providers from proceeding without meeting these requirements, imposing fines up to $100,000 or one year in prison per violation. Medical emergencies requiring immediate treatment are exempt, as are cases where parental notification is impossible due to the emergency. This law directly affects minors seeking abortions, their parents/guardians, and healthcare providers receiving federal funds or operating across state lines.

Maddy summaryThis bill amends rules to improve access to generic drugs and biosimilars by requiring brand-name drug manufacturers (license holders) to provide samples for development. It establishes a "designated delivery service" standard for overnight/2-day shipping and sets strict timelines: the FDA must respond to sample requests within 60 days for non-clinical testing or 120 days for clinical trials. Manufacturers must publicly post clear policies within 45 days of product approval, including contact details, request procedures, and responsible officers. These changes directly affect generic drug developers seeking samples and brand companies managing product access. The bill focuses on streamlining the sample request process to accelerate generic drug development without altering drug safety requirements.

Maddy summaryThis bill requires abortion providers to offer patients specific disposal options for fetal remains after an abortion, including taking the remains or having the provider arrange interment or cremation. Providers must obtain patient consent in writing for disposal choices and retain these records. If patients choose provider disposal, providers must arrange final disposition (interment or cremation) within 7 days, with penalties including fines up to $50,000 for documentation failures or criminal charges for non-compliance. Annual reports on procedures and disposal methods are also mandated for providers and the Secretary of Health.

Maddy summaryThe ADAPT 2.0 Act (S 1132) allows U.S. drug manufacturers to seek approval for new drugs using clinical and safety data from countries where the drug is already approved, such as the United Kingdom and South Africa. It requires the FDA to review these applications within 90 days and automatically approve them if the drug meets specific criteria, including being approved in the foreign country, safe, effective, and meeting manufacturing and patent requirements. The bill mandates the FDA to establish a new Foreign Drug Review Advisory Committee to evaluate applications within 60 days and publish approval decisions online. It also requires sponsors to conduct post-approval studies for certain drugs and submit promotional materials for review before dissemination. This law directly affects drug manufacturers seeking faster U.S. market access and the FDA’s review process for foreign-approved therapies.

Maddy summaryThis bill repeals two specific legal authorizations for U.S. military force against Iraq: the 1991 authorization (Public Law 102-1) and the 2002 authorization (Public Law 107-243). If enacted, it would end the legal basis for military operations in Iraq under these two resolutions. The repeal directly affects the executive branch’s authority to use military force against Iraq under these specific laws. It does not create new policy but removes existing legal permissions.

Maddy summaryThis bill (S 1021) prohibits the Export-Import Bank of the United States from providing financing to any business or project where the applicant or any participant has "seriously delinquent tax debt" - meaning unpaid federal taxes assessed by the IRS that could be collected through levy or court action. The Bank must verify tax debt status using the System for Award Management website and IRS data, and cannot finance such entities unless the President grants a waiver for urgent national interests (with a 30-day report to Congress). The bill specifically excludes debts being paid under an agreement, under active dispute, or subject to a continuous levy. It directly affects businesses seeking U.S. export financing who owe significant unpaid federal taxes.

Maddy summaryS 1054, the IRS Improper Payments Act, requires the Internal Revenue Service (IRS) to reduce incorrect tax refunds or credits (improper payments) by setting annual targets and publicly reporting progress. The bill mandates the IRS to publish online data on improper payment rates, recovery efforts, and causes of errors, while designating an official accountable for meeting reduction goals without harming taxpayer services. Annual reports to Congress and the Treasury Inspector General will detail methodology, reduction plans, and measures to avoid burdening taxpayers. If the IRS fails to improve improper payments for two consecutive years, it must submit a remedial plan for review by oversight bodies.

Protect Taxpayers' Privacy Act This bill increases to $250,000 the criminal penalty for unauthorized disclosures of taxpayer information by federal employees and tax return preparers. It also lowers the evidentiary requirements for removal of employees from federal service who disclose tax return information without authorization.